Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
LANKAU PETER A
   2. Issuer Name and Ticker or Trading Symbol
ENDO PHARMACEUTICALS HOLDINGS INC [ENDP] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President & CEO
(Last)
(First)
(Middle)
100 ENDO BOULEVARD		 3. Date of Earliest Transaction (Month/Day/Year)
06/01/2006
(Street)

CHADDS FORD, PA 19317		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $.01 per share 06/01/2006   M   43,652 A (1) 1,244,827 (2) D  
Common Stock, par value $.01 per share 06/01/2006   S   43,652 (3) D $ 29.5965 1,201,175 (4) D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options granted pursuant to 2000 Stock Incentive Plan (1) 06/01/2006   M     43,652   (5)   (6) Common Stock 43,652 $ 0 351,911 (7) D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
LANKAU PETER A
100 ENDO BOULEVARD
CHADDS FORD, PA 19317		   X     President & CEO  

Signatures

 /s/ Peter A. Lankau   06/05/2006
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Of the 43,652 shares sold here, 8,174 were underlying stock options with an exercise price of $7.25 per share, 27,389 were underlying stock options with an exercise price of $9.40 per share and 8,089 were underlying stock options with an exercise price of $9.17 per share.
(2) Mr. Lankau's beneficial ownership includes 67,399 shares of Endo common stock and 1,177,428 shares underlying options granted under the Endo Pharmaceuticals Holdings Inc. 2000 and 2004 Stock Incentive Plans, 480,791 of which are currently exercisable.
(3) As previously disclosed, Mr. Lankau had placed 436,520 of the shares underlying his stock options into a 10b5-1 pre-set selling program for a period of approximately 24 months, which began on March 1, 2006 (the "Lankau Pre-Set Selling Program"). The shares sold here were sold pursuant to the Lankau Pre-Set Selling Program, which leaves 261,912 shares (underlying options) in the Lankau Pre-Set Selling Program as of June 5, 2006.
(4) Mr. Lankau's beneficial ownership includes 23,747 shares of Endo common stock and 1,177,428 shares underlying options granted under the Endo Pharmaceuticals Holdings Inc. 2000 and 2004 Stock Incentive Plans, 480,791 of which are currently exercisable. The 43,652 shares sold here were sold pursuant to the Lankau Pre-Set Selling Program, which leaves 261,912 shares (underlying options) in the Lankau Pre-Set Selling Program as of June 5, 2006.
(5) Of the 43,652 shares sold here, 8,174 of the related stock options were exercisable on 10/13/2004, 6,847 of the related stock options were exercisable on 8/8/2002, 6,847 of the related stock options were exercisable on 8/8/2003, 6,847 of the related stock options were exercisable on 8/8/2004, 6,848 of the related stock options were exercisable on 8/8/2005, and 8,089 of the related stock options were exercisable on 9/19/2003.
(6) Of the 43,652 shares sold here, 8,174 were underlying stock options with an expiration date of 10/13/2010, 27,389 were underlying stock options with an expiration date of 8/8/2011 and 8,089 were underlying stock options with an expiration date of 9/19/2012.
(7) This number represents the remainder of the 9/19/2002 grant to Mr. Lankau of 360,000 options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.